By Bernadette Toner
NEW YORK (GenomeWeb News) – Life Technologies said today that it has signed an exclusive license agreement for technology that enables synthetic biologists to selectively modify the gene expression of genetically engineered organisms.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: new chromatin imaging approach, and more.
University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.
Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.
Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.